Has AI Reached Peak Hype?

Posted by Arun Shastri on Wed, May 08, 2019

Pratap Khedkar co-wrote this blog post with Arun Shastri.

At The Wall Street Journal Health Forum, held in Washington D.C. on April 30, Novartis Chief Executive Vas Narasimhan called artificial intelligence “another tool in the toolbox.” This viewpoint diverges from recent notions that AI is a critical capability that’s going to change the way that pharma companies do business. In fact, industry experts have hoped that the dwindling return on investments for R&D (the current 3% ROI is predicted to hit 0% by 2020) could be reversed by employing AI-based technologies in drug discovery. There are more than 100 AI startups in this field that have received generous investments from venture capital. Yet, IBM has discontinued sales of its Watson AI system for drug discovery.


>
Read More

The CVS/Aetna Merger Got the Greenlight, but Pharma Is Stuck at an Imaginary Red

Posted by Paul Darling on Mon, Oct 15, 2018

CVS Health and Aetna. Cigna and Express Scripts. Amazon, Berkshire Hathaway and JPMorgan Chase. Each one of these deals is evidence that corporate America will continue to march into the medical arena, uniting once-distinct healthcare enterprises under one roof. While the long-held divisions between U.S. healthcare stakeholders may be getting hazy, the aim is clear: to deliver convenient, high-quality care to consumers at a lower cost.


>
Read More